Successful Treatment of Severe Autoimmune Hemolytic Anemia with Rituximab
Author Information
Author(s): Gupta Shilpi, Szerszen Anita, Nakhl Fadi, Varma Seema, Gottesman Aaron, Forte Frank, Dhar Meekoo
Primary Institution: Staten Island University Hospital
Hypothesis
Can rituximab effectively treat severe mixed autoimmune hemolytic anemia that does not respond to steroids?
Conclusion
A single cycle of rituximab led to complete resolution of severe mixed autoimmune hemolytic anemia in a patient who did not respond to steroid therapy.
Supporting Evidence
- The patient had severe anemia and did not respond to initial steroid treatment.
- After four weeks of rituximab therapy, the patient's hemoglobin stabilized and he became transfusion-independent.
- At a two-year follow-up, the patient remained in complete remission.
Takeaway
A man with a serious blood condition got better after just one treatment with a medicine called rituximab, even though other treatments didn't work.
Methodology
The patient was treated with rituximab after failing to respond to steroids and plasmapheresis.
Limitations
This is a single case report, limiting generalizability.
Participant Demographics
62-year-old Caucasian man.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website